1. Pink Sheet
  3. >>Europe
  4. >>United Kingdom

Amicus Wins English Funding For Pombiliti/Opfolda, Immunocore To Appeal Kimmtrak Rejection

 
• By Neena Brizmohun

Amicus is launching its Pompe disease treatment Pombiliti/Opfolda in the UK after announcing on the same day that it had secured reimbursement and marketing approval for the combination treatment. Meanwhile, Immunocore says it disagrees with NICE's rejection of its advanced uveal melanoma drug, Kimmtrak.

cost effectiveness
NICE assesses the cost effectiveness of medicines for use in England and Wales • Source: Shutterstock

NICE has recommended in favor of funding Amicus Therapeutics’ Pompe disease therapy, Pombiliti plus Opfolda, via the National Health Service in England, but it is standing firm on its previous rejection of Immunocore’s treatment for advanced uveal melanoma, Kimmtrak.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United Kingdom

More from Europe